- Investing.com
Metrics to compare | 2257 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2257PeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.2x | −2.6x | −0.5x | |
PEG Ratio | −0.08 | −0.07 | 0.00 | |
Price/Book | −9.0x | 2.6x | 2.6x | |
Price / LTM Sales | - | 127.3x | 3.2x | |
Upside (Analyst Target) | - | 176.7% | 48.8% | |
Fair Value Upside | Unlock | 9.3% | 6.9% | Unlock |
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors. The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement diseases. In addition, it is developing STP247G to treat complement-mediated immunologic diseases; STP237G for the treatment of hypertension in combination with familial hypertriglyceridemia; and STP136G to treat hypertension. The company was founded in 2007 and is based in Wan Chai, Hong Kong.